
Opinion|Videos|February 14, 2025
MCL Therapy Selection and Sequencing
Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.
Advertisement
Episodes in this series

- What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
- How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
3
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
4
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
5





